Utility of balloon aortic valvuloplasty in the transcatheter aortic valve implantation era.
aortic valve disease
quality of care and outcomes
valvular disease
valvuloplasty
Journal
Open heart
ISSN: 2053-3624
Titre abrégé: Open Heart
Pays: England
ID NLM: 101631219
Informations de publication
Date de publication:
04 2020
04 2020
Historique:
received:
16
11
2019
revised:
23
01
2020
accepted:
10
02
2020
entrez:
29
4
2020
pubmed:
29
4
2020
medline:
1
7
2020
Statut:
ppublish
Résumé
Balloon aortic valvuloplasty (BAV) has seen renewed interest since the advent of transcatheter aortic valve implantation (TAVI). The study aimed to characterise a contemporary BAV cohort and determinants of clinical outcomes. Patients undergoing BAV at a single tertiary centre were retrospectively reviewed over a 10-year period, and functional and mortality outcomes were reported with up to a 2-year follow-up. 224 patients (aged 82.5±8.3 years; 48% female) underwent BAV over the study period. Indications were either destination treatment (39%) or bridge-to-valve replacement (61%)-including bridge-to-decision (29%), symptom relief while on the waitlist (27%), and temporary contraindications to TAVI/aortic valve replacement (AVR) (5%). The mean reduction of aortic mean pressure gradient was 38%. Procedural mortality occurred in 0.5%, stroke in 1.3%, and major bleeding in 0.9%. Twelve-month mortality was 36% overall, and 26% and 50% in the bridging and destination groups, respectively. New York HeartAssociation (NYHA) class improved by ≥1 at 30 days in 50%. Among the bridge-to-TAVI/AVR group, 40% proceeded to TAVI/AVR within 12 months following BAV. In multivariate analysis, active malignancy at baseline (OR: 4.4, 95% CI: 1.3 to 15.1, p=0.02), smoking history (OR: 3.3, 95% CI: 1.3 to 7.9, p<0.01), LVEF ≤30% at baseline (OR: 3.2, 95% CI: 1.3 to 7.6, p<0.01), destination treatment (OR: 2.2, 95% CI: 1.0 to 4.9, p=0.04) were all associated with 12-month mortality. BAV remains a useful procedure with relatively low rates of complications, however, 1-year mortality rates are high. Contemporary indications for BAV include a bridge to definitive valve replacement or destination treatment.
Sections du résumé
BACKGROUND
Balloon aortic valvuloplasty (BAV) has seen renewed interest since the advent of transcatheter aortic valve implantation (TAVI). The study aimed to characterise a contemporary BAV cohort and determinants of clinical outcomes.
METHODS
Patients undergoing BAV at a single tertiary centre were retrospectively reviewed over a 10-year period, and functional and mortality outcomes were reported with up to a 2-year follow-up.
RESULTS
224 patients (aged 82.5±8.3 years; 48% female) underwent BAV over the study period. Indications were either destination treatment (39%) or bridge-to-valve replacement (61%)-including bridge-to-decision (29%), symptom relief while on the waitlist (27%), and temporary contraindications to TAVI/aortic valve replacement (AVR) (5%). The mean reduction of aortic mean pressure gradient was 38%. Procedural mortality occurred in 0.5%, stroke in 1.3%, and major bleeding in 0.9%. Twelve-month mortality was 36% overall, and 26% and 50% in the bridging and destination groups, respectively. New York HeartAssociation (NYHA) class improved by ≥1 at 30 days in 50%. Among the bridge-to-TAVI/AVR group, 40% proceeded to TAVI/AVR within 12 months following BAV. In multivariate analysis, active malignancy at baseline (OR: 4.4, 95% CI: 1.3 to 15.1, p=0.02), smoking history (OR: 3.3, 95% CI: 1.3 to 7.9, p<0.01), LVEF ≤30% at baseline (OR: 3.2, 95% CI: 1.3 to 7.6, p<0.01), destination treatment (OR: 2.2, 95% CI: 1.0 to 4.9, p=0.04) were all associated with 12-month mortality.
CONCLUSIONS
BAV remains a useful procedure with relatively low rates of complications, however, 1-year mortality rates are high. Contemporary indications for BAV include a bridge to definitive valve replacement or destination treatment.
Identifiants
pubmed: 32341170
pii: openhrt-2019-001208
doi: 10.1136/openhrt-2019-001208
pmc: PMC7204556
pii:
doi:
Types de publication
Journal Article
Observational Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
N Engl J Med. 1988 Jul 21;319(3):125-30
pubmed: 3386691
Catheter Cardiovasc Interv. 2013 Feb;81(2):366-73
pubmed: 22730270
J Geriatr Cardiol. 2016 Sep;13(6):475-82
pubmed: 27582761
JACC Cardiovasc Interv. 2010 Jun;3(6):660-8
pubmed: 20630460
Catheter Cardiovasc Interv. 2017 Aug 1;90(2):303-310
pubmed: 27514931
Circulation. 2007 May 1;115(17):2344-51
pubmed: 17470709
Circ Cardiovasc Interv. 2017 May;10(5):
pubmed: 28495894
Can J Cardiol. 2014 Oct;30(10):1162-9
pubmed: 25047363
EuroIntervention. 2016 Jan 22;11(9):1029-33
pubmed: 26384006
Catheter Cardiovasc Interv. 2013 Feb;81(2):358-63
pubmed: 22566394
Circulation. 1989 Jun;79(6):1189-96
pubmed: 2470529
Clin Cardiol. 2015 Feb;38(2):76-81
pubmed: 25649013
Heart Lung Circ. 2015 Mar;24(3):281-90
pubmed: 25456213
J Am Coll Cardiol. 2017 Jul 11;70(2):252-289
pubmed: 28315732
Catheter Cardiovasc Interv. 2013 Oct 1;82(4):632-7
pubmed: 23015369
J Am Coll Cardiol. 1995 Nov 15;26(6):1522-8
pubmed: 7594080
Heart. 2018 Jan;104(1):23-29
pubmed: 28566471
Am Heart J. 2014 Feb;167(2):235-40
pubmed: 24439985
Heart Lung Circ. 2008;17 Suppl 4:S73-81
pubmed: 19010083
J Am Coll Cardiol. 2017 Mar 14;69(10):1215-1230
pubmed: 27956264
Am J Med. 2014 Aug;127(8):744-753.e3
pubmed: 24608018
JACC Cardiovasc Interv. 2015 Feb;8(2):324-333
pubmed: 25700756
Circulation. 1994 Feb;89(2):642-50
pubmed: 8313553
Intern Emerg Med. 2014 Apr;9(3):345-7
pubmed: 23824445
Am Heart J. 2015 Jul;170(1):180-6
pubmed: 26093880
Circ Cardiovasc Interv. 2017 May;10(5):
pubmed: 28495898
Radiol Oncol. 2014 Jan 22;48(1):62-6
pubmed: 24587781
J Am Coll Cardiol. 2014 Jun 10;63(22):e57-185
pubmed: 24603191
Ann Thorac Surg. 2016 Feb;101(2):592-7; discussion 597-8
pubmed: 26410157
J Invasive Cardiol. 2015 Dec;27(12):547-53
pubmed: 26630642
EuroIntervention. 2013 Apr 22;8(12):1388-97
pubmed: 23680956
Lancet. 1986 Jan 11;1(8472):63-7
pubmed: 2867315
J Am Coll Cardiol. 1994 Apr;23(5):1071-5
pubmed: 8144770
Circulation. 2011 Jun 14;123(23):2736-47
pubmed: 21670242